PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry – FDA

Опубликовано 3 октября, 201817 декабря, 2018 frozencat

Обновление руководства FDA:

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry

Руководство замещает Adaptive Design Clinical Trials for Drugs and Biologics – 2010.

Рубрики: Блог

Навигация по записям

Предыдущая запись: Определение объема выборки для исследований биоэквивалентности с использованием компьютерного моделирования
Следующая запись: Работа с данными в IBM SPSS: присвоение меток переменным из другого источника

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20180202 170517
20180202 170838(0)
20180816 145328
IMG-20170807-WA0037
20170803 001141
20180202 123641
  • Laboratory Information Bulletins
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-07-09 By FDA
  • Human medicines European public assessment report (EPAR): Hetlioz, tasimelteon, Date of authorisation: 03/07/2015, Revision: 9, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-09
  • Human medicines European public assessment report (EPAR): Toujeo (previously Optisulin), insulin glargine, Date of authorisation: 26/06/2000, Revision: 37, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-09
  • Human medicines European public assessment report (EPAR): Duvyzat, givinostat, Date of authorisation: 06/06/2025, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-09
  • Bayesian Statistical Analysis (BSA) Demonstration Project
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-09 By FDA
  • Human medicines European public assessment report (EPAR): Braftovi, encorafenib, Date of authorisation: 19/09/2018, Revision: 16, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-09
  • Compounding Quality Center of Excellence | Annual Conference - 08/25/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-09 By FDA
  • Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-09 By FDA
  • Generic Drug User Fee Amendments
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-09 By FDA
  • Institutional Review Board (IRB) Written Procedures
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-09 By FDA
  • User Fee Lists
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-09 By FDA
  • Human medicines European public assessment report (EPAR): Benlysta, belimumab, Date of authorisation: 13/07/2011, Revision: 38, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-09
  • Compounding Quality Center of Excellence | Annual Conference
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-09 By FDA
  • Human medicines European public assessment report (EPAR): Ozempic, semaglutide, Date of authorisation: 08/02/2018, Revision: 16, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-09
  • Human medicines European public assessment report (EPAR): Exjade, deferasirox, Date of authorisation: 28/08/2006, Revision: 54, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-09
Предыдущие записи
Тема: Scaffold от Danny Cooper.